White blood cell disorders:
Indications for: ROLVEDON
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia.
Limitations of Use:
Not for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Give 13.2mg by SC inj once per chemotherapy cycle. Administer ~24 hours after cytotoxic chemotherapy. Do not give within the period from 14 days before to 24 hours after administration of cytotoxic chemotherapy.
History of serious allergic reactions, including anaphylaxis, to eflapegrastim, pegfilgrastim, or filgrastim products.
Monitor for enlarged spleen or splenic rupture, and for acute respiratory distress syndrome (ARDS); evaluate if symptoms occur; discontinue if ARDS is diagnosed. Permanently discontinue if serious allergic reactions occur. Sickle cell disorders; discontinue if sickle cell crisis occurs. Evaluate if glomerulonephritis is suspected; consider dose reduction or interruption if treatment-related. Monitor CBCs, platelets during therapy; discontinue if WBC count ≥100x109/L occurs. Monitor closely if symptoms of capillary leak syndrome develop. Discontinue if aortitis is suspected. Tumor growth factor (eg, myeloid malignancies, myelodysplasia). Monitor for MDS/AML in those with breast or lung cancer. Possible transient (+) bone imaging changes in nuclear imaging. Pregnancy. Nursing mothers.
Granulocyte colony stimulating factor.
Fatigue, nausea, diarrhea, bone pain, headache, pyrexia, anemia, rash, myalgia, arthralgia, back pain; ARDS, splenic rupture, glomerulonephritis, leukocytosis, capillary leak syndrome, thrombocytopenia.
Generic Drug Availability:
Single-dose prefilled syringe—1 (w. supplies)